FMT+ QL1706+ bevacizumab+ Xelox作为高级MSS型结肠癌与肝转移的一线治疗
粪便菌群移植与QL1706,贝伐单抗和Xelox结合在一起,作为肝转移的晚期MSS型结肠癌的一线治疗:预期,多中心,单臂II期探索性试验的研究方案
The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 30 patients with advanced colorectal cancer patients with liver metastasis who have not received prior treatment. This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with QL1706+Bevacizumab+XELOX to enhance the anti-tumor immune effect at the same time, thereby improving the prognosis of colorectal cancer patients with liver metastasis.
研究概览
详细说明
This is a prospective, single-arm, multi-center, exploratory clinical study. Patients with previously untreated, newly diagnosed advanced colorectal cancer with liver metastasis, who could be diagnosed by histological or cytological means, ECOG PS 0-1, excluded Ras, Raf wild type left colon/rectum, excluded dMMR/MSI-H. Eligible subjects who met the inclusion criteria were screened and signed informed consent.
FMT was performed 2 days after treatment with bevacizumab, and chemotherapy. QL1706, bevacizumab, and chemotherapy (XELOX) were administered every 3 weeks according to the patient's body surface area. A total of 6 cycles were performed. Subsequent maintenance therapy was at the discretion of the investigator.
RECIST v1.1 was used for tumor evaluation every 6 weeks during treatment. NCI-CTCAE 5.0 was used for safety assessment every 3 weeks. Adverse events were recorded throughout the study to 90 days after the end of treatment. Treatment continues until disease progression, subject withdraws informed consent, loss of follow-up, or death. Patients should provide 10ml whole blood samples and fecal samples at baseline, after two cycles of treatment, after four cycles of treatment, before maintenance treatment for the detection of efficacy prediction markers (each cycle is 21 days).
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Hua Jiang MD
- 电话号码:+86-18015852711
- 邮箱:czeyjh@njmu.edu.cn
学习地点
-
-
-
Changzhou、中国
- 招聘中
- The Second People's Hospital of Changzhou
-
接触:
- Hua Jiang MD
- 电话号码:+86-18015852711
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histological or cytological confirmed advanced colorectal cancer with liver metastasis.
- Signed written informed consent.
- Have not received anti-tumor treatment.
- According to the investigators assessment, at least one measurable target lesion defined by RECIST v1.1.
- Patients of both sexes, aged ≥18 years and ≤75 years.
- ECOG PS 0-1;
- Expected survival time ≥ 3 months;
- Have adequate organ and bone marrow function, laboratory examination within 7 days prior to enrollment meets the following requirements, as follows:
1) Blood routine: ANC ≥ 1.5 × 10^9/L, Platelet count ≥ 100 × 10^9/L, HGB ≥100 g/L (no blood transfusion or erythropoietin dependence within 14 days); 2) Liver function: TBIL ≤1.5 x ULN; ALT/AST ≤ 5 x ULN; ALP ≤5×ULN; 3) Renal function: Cr ≤1.5×ULN, or creatinine clearance ≥50 mL/min: Urine routine results showed urinary protein < 2+; 4) Coagulation function: INR or PT ≤1.5 x ULN. 9.For female subjects of reproductive age, a urine or serum pregnancy test should be performed and the result is negative 3 days prior to receiving the initial study drug administration.
10. For women of childbearing potential (WOCBP): agreement to refrain from heterosexual intercourse or use contraception.
11. For men: agreement to refrain from heterosexual intercourse or use a condom, and agreement to refrain from donating sperm.
Exclusion Criteria:
- Suffered from other malignancies in the past 5 years, excluding cured basal cell carcinoma of the skin, cervical carcinoma in situ and papillary thyroid carcinoma.
- Patients requiring elective surgery during the trial.
- Patients who cannot take oral drugs, or have conditions that the investigator determines to significantly affect gastrointestinal absorption, such as chronic diarrhea, intestinal obstruction, etc., and are not suitable for treatment.
- Patients during pregnancy (positive pregnancy test) or lactation.
- Central nervous system metastasis or meningeal metastasis.
- Uncontrollable bone metastasis, or patients at risk of fracture, requiring surgery, local radiation therapy.
- Patients with active infection requiring systemic anti-infection treatment.
- Patients with a history of immunodeficiency, including those who are positive for HIV antibody tests.
- Patients with known, active autoimmune diseases.
- Patients with uncontrolled active hepatitis B, patients with hepatitis C virus infection (HCV antibody positive).
- A history of severe cardiovascular and cerebrovascular diseases, including but not limited to: severe arrhythmia, acute coronary syndrome within 6 months, congestive heart failure, aortic dissection, stroke, and T IA history.
- Severe bleeding events occur within half a year, or high bleeding risk factors such as active digestive tract ulcers and esophageal and gastric varices due to liver cirrhosis.
- Patients with diabetes who cannot be stably controlled by drugs (including insulin).
- Mental or language disorders that prevent communication with the patient;
- Patients participating in another clinical trial.
- MSI-H/ d MMR without immunotherapy; left colorectum of Ras, Raf wild-type.
- The investigator believes that the subject has other serious systemic diseases or other conditions that make him unsuitable for participation in this trial.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:FMT+QL1706+bevacizumab+Xelox
|
Participants will receive FMT combined with QL1706+Bevacizumab+XELOX for 6 cycles. If there is no progression of the disease after 6 cycles of the first-line treatment, then patients will enter the maintenance treatment stage. The therapy of maintenance treatment stage was at the discretion of the investigator. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective Response Rate (ORR)
大体时间:up to 24 months
|
Objective response rate will be assessed by investigators. |
up to 24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Median Progression-Free Survival (mPFS)
大体时间:up to 24 months
|
Observation for mPFS will be recorded until the end of follow-up after the start of 1st cycle of treatment. |
up to 24 months
|
|
Median Overall Survival (mOS)
大体时间:up to 24 months
|
The time from the first treatment to death from any cause. |
up to 24 months
|
|
6-Months Progression-Free Survival Rate (6month-PFS)
大体时间:up to 6 months
|
The proportion of patients whose disease did not progress 6 months after treatment |
up to 6 months
|
|
12-Months Progression-Free Survival Rate (12month-PFS)
大体时间:up to 12 months
|
The proportion of patients whose disease did not progress 12 months after treatment |
up to 12 months
|
|
18-Months Progression-Free Survival Rate (18month-PFS)
大体时间:up to 18 months
|
The proportion of patients whose disease did not progress 18 months after treatment |
up to 18 months
|
|
6-Months overall survival rate(6-Months-OS Rate)
大体时间:up to 6 months
|
The proportion of patients who have not died after 6-Months of treatment |
up to 6 months
|
|
12-Months overall survival rate(12-Months-OS Rate)
大体时间:up to 12 months
|
The proportion of patients whose disease did not progress 12 months after treatment |
up to 12 months
|
|
18-Months overall survival rate(18-Monthsr-OS Rate)
大体时间:up to 18 months
|
The proportion of patients who have not died after 18 months of treatment |
up to 18 months
|
|
Objective Response Rate (ORR) of liver metastases
大体时间:up to 24 months
|
Objective response rate will be assessed by investigators. |
up to 24 months
|
|
Disease Control Rate (DCR)
大体时间:up to 24 months
|
The proportion of patients whose tumors achieve a response (CR+PR) and stable disease (SD) after treatment for the minimum duration required. |
up to 24 months
|
|
Surgical conversion rate
大体时间:up to 24 months
|
Proportion of inoperable patients converted to operable. |
up to 24 months
|
|
Incidence of Adverse events (AEs)
大体时间:up to 24 months
|
Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0). |
up to 24 months
|
|
Quality of Life (QoL)
大体时间:up to 24 months
|
QoL(quality of life) will be evaluated by EORTC-QLQ-C30.The total score ranges from 0 to 60, with higher scores indicating better quality of life |
up to 24 months
|
|
The Diversity of Fecal Microbiota
大体时间:up to 24 months
|
This will be detected by 16s rRNA sequencing or metagenomes. |
up to 24 months
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- [2025]YLJSA057-01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.